158 related articles for article (PubMed ID: 38491717)
1. Preclinical metabolism and the disposition of vornorexant/TS-142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Konno Y; Kamigaso S; Toki H; Terasaka S; Hikichi H; Endo H; Yamaguchi JI; Mizuno-Yasuhira A
Pharmacol Res Perspect; 2024 Apr; 12(2):e1183. PubMed ID: 38491717
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS-142 in healthy Japanese participants following single/multiple dosing: Randomized, double-blind, placebo-controlled phase-1 studies.
Kambe D; Hasegawa S; Imadera Y; Mano Y; Matsushita I; Konno Y; Ogo H; Uchimura N; Uchiyama M
Basic Clin Pharmacol Toxicol; 2023 Nov; 133(5):576-591. PubMed ID: 37563858
[TBL] [Abstract][Full Text] [Related]
3. Disposition and Metabolism of [
Ueno T; Ishida T; Aluri J; Suzuki M; Beuckmann CT; Kameyama T; Asakura S; Kusano K
Drug Metab Dispos; 2021 Jan; 49(1):31-38. PubMed ID: 33144331
[TBL] [Abstract][Full Text] [Related]
4. Disposition and metabolism of [
Ueno T; Ishida T; Kusano K
Xenobiotica; 2019 Jun; 49(6):688-697. PubMed ID: 29806508
[TBL] [Abstract][Full Text] [Related]
5. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D
Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533
[TBL] [Abstract][Full Text] [Related]
6. Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
Hasegawa M; Chino Y; Horiuchi N; Hachiuma K; Ishida M; Fukasawa Y; Nakai Y; Yamaguchi J
Xenobiotica; 2015; 45(12):1105-15. PubMed ID: 26489961
[TBL] [Abstract][Full Text] [Related]
7. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.
Gotter AL; Winrow CJ; Brunner J; Garson SL; Fox SV; Binns J; Harrell CM; Cui D; Yee KL; Stiteler M; Stevens J; Savitz A; Tannenbaum PL; Tye SJ; McDonald T; Yao L; Kuduk SD; Uslaner J; Coleman PJ; Renger JJ
BMC Neurosci; 2013 Aug; 14():90. PubMed ID: 23981345
[TBL] [Abstract][Full Text] [Related]
8. Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR.
Mutlib AE; Shockcor J; Chen SY; Espina RJ; Pinto DJ; Orwat MJ; Prakash SR; Gan LS
Chem Res Toxicol; 2002 Jan; 15(1):48-62. PubMed ID: 11800597
[TBL] [Abstract][Full Text] [Related]
9. The metabolism of the dual orexin receptor antagonist daridorexant.
Treiber A; Delahaye S; Weigel A; Aeänismaa P; Gatfield J; Seeland S
Xenobiotica; 2023 Mar; 53(3):173-183. PubMed ID: 36809238
[TBL] [Abstract][Full Text] [Related]
10. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug metabolism of green tea catechins in human, monkey, dog, rat and mouse hepatocytes.
Chen WW; Qin GY; Zhang T; Feng WY
Drug Metab Lett; 2012 Jun; 6(2):73-93. PubMed ID: 22594564
[TBL] [Abstract][Full Text] [Related]
12. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
13. Excretion, metabolism, and pharmacokinetics of CP-945,598, a selective cannabinoid receptor antagonist, in rats, mice, and dogs.
Miao Z; Scott DO; Griffith DA; Day R; Prakash C
Drug Metab Dispos; 2011 Dec; 39(12):2191-208. PubMed ID: 21875952
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
15. Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist.
Suzuki R; Nozawa D; Futamura A; Nishikawa-Shimono R; Abe M; Hattori N; Ohta H; Araki Y; Kambe D; Ohmichi M; Tokura S; Aoki T; Ohtake N; Kawamoto H
Bioorg Med Chem; 2015 Mar; 23(6):1260-75. PubMed ID: 25693785
[TBL] [Abstract][Full Text] [Related]
16. Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats.
Forkuo AD; Ansah C; Pearson D; Gertsch W; Cirello A; Amaral A; Spear J; Wright CW; Rynn C
BMC Pharmacol Toxicol; 2017 Dec; 18(1):84. PubMed ID: 29273084
[TBL] [Abstract][Full Text] [Related]
17. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
[TBL] [Abstract][Full Text] [Related]
18. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and Disposition of [
Bolleddula J; Chen H; Cohen L; Zhou X; Pusalkar S; Berger A; Sedarati F; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2022 Jul; 50(7):989-997. PubMed ID: 35504658
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia.
Ziemichód W; Grabowska K; Kurowska A; Biała G
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]